in neocortex folding at E18.5, reminiscent of gyrification, a hallmark of human neocortex (Fig. 4) . Cortical plate area in the gyrus-like structures was increased compared with the contralateral smooth neocortex, with proper cortical lamination.
The methodology for isolation of cortical progenitor subpopulations established here can be applied to other mammalian species, including primates, opening avenues for comparative evolutionary studies. Furthermore, the present transcriptome data provide insight into molecular differences between the various types of cortical NPCs in developing mouse and human neocortex and constitute a resource for future studies. A very recent, independent analysis of human radial glia transcriptome (19) has concentrated on genes present in both mouse and human genomes but expressed only in human cortical progenitors, identifying a role for platelet-derived growth factor signaling (16) in human radial glia. In contrast, we focus here on genes present only in the human, but not mouse, genome and highly expressed in basal radial glia.
Thus, we identify ARHGAP11B as a humanspecific gene that amplifies basal progenitors and is capable of causing neocortex folding in mice (33, 34) . This probably reflects a role for ARHGAP11B in development and evolutionary expansion of the human neocortex, a conclusion consistent with the finding that the gene duplication that created ARHGAP11B occurred on the human lineage after the divergence from the chimpanzee lineage but before the divergence from Neandertals, whose brain size was similar to that of modern humans.
Note added in proof: In work published after online publication of this paper, Johnson et al. (35) used a complementary approach to similarly isolate and compare the transcriptomes of human and mouse apical and basal radial glia.
We apologize to all researchers whose work could not be cited due to space limitation. We are grateful to the Services and Facilities of the MPI-CBG for the outstanding support provided, notably J. 
PARASITOLOGY
The in vivo dynamics of antigenic variation in Trypanosoma brucei Monica R. Mugnier, George A. M. Cross, F. Nina Papavasiliou* Trypanosoma brucei, a causative agent of African Sleeping Sickness, constantly changes its dense variant surface glycoprotein (VSG) coat to avoid elimination by the immune system of its mammalian host, using an extensive repertoire of dedicated genes. However, the dynamics of VSG expression in T. brucei during an infection are poorly understood. We have developed a method, based on de novo assembly of VSGs, for quantitatively examining the diversity of expressed VSGs in any population of trypanosomes and monitored VSG population dynamics in vivo. Our experiments revealed unexpected diversity within parasite populations and a mechanism for diversifying the genome-encoded VSG repertoire. The interaction between T. brucei and its host is substantially more dynamic and nuanced than previously expected.
T he protozoan parasite Trypanosoma brucei, a major cause of human and animal Trypanosomiasis, lives extracellularly within its mammalian host, where it is constantly exposed to the host immune system. T. brucei has evolved a mechanism for antigenic variation during infection in which the parasite can turn on and off variant surface glycoprotein (VSG)-encoding genes from a genomic repertoire of~2000 different genes (1). Each parasite expresses one VSG at a time, from one of~15 telomeric expression sites (2); the rest (silent VSGs) sit in silent expression sites or in other genomic locations (1). The highly antigenic VSG is so densely packed on T. brucei's surface that it obscures other cell-surface components from immune recognition. At any time, a few parasites in a population will stochastically switch their VSG. As previous variants are recognized by the immune system and cleared, newly switched variants emerge, giving rise to characteristic waves of parasitemia (3). These waves have long been interpreted as the sequential expression and clearance of one or a few VSGs, a notion supported by experimental evidence that relied on low-resolution approaches (4) (5) (6) (7) (8) .
Despite attempts at modeling, little is known about the kinetics of VSG expression during infection (9) (10) (11) (12) . To assess this, we developed a targeted RNA sequencing (RNA-seq) approach, termed VSG-seq, in which VSG cDNA, amplified by using conserved sequences at the 5′ and 3′ end of every mature VSG mRNA ( fig. S1) , is sequenced and then assembled de novo by a transcriptome reconstruction method called Trinity (13) . We validated this approach using mixtures of T. brucei cell lines expressing specific VSGs in known proportions ( Fig. 1 and fig. S1 ). We compared measured expression of each VSG in the control populations with the known input and found that we could accurately assemble a VSG sequence expressed in as few as nine cells in the control mixture. VSG-seq is capable of reliably detecting variants present on 0.01% of parasites and quantifying a variant's presence within the population, for variants present above 0.1% of the population (Fig. 1B and fig. S1 ). The apparent overestimation of minor VSGs in this control experiment is likely a result of low-level switching in the more abundant components of the mixture or low-level transcription of silent VSGs. The limits of detection and quantification for VSGseq appear to be independent of starting cell number because control mixtures made from 10 6 or 10 7 cells show similar results (Fig. 1B and fig. S1 ).
To measure VSG expression within populations of T. brucei, we infected four mice with 5 EATRO1125 parasites-originally expressing VSG AnTat1.1 (14, 15) but now heterogeneous and each expressing a distinct VSG-and tracked VSG expression dynamics for 30 days. A few variants made up the majority of the population at each time, but surprisingly, each sample also contained many rare variants that would have been undetectable by using previous approaches ( Fig.  2A and fig. S2 ). Infections showed great diversity even within parasitemic valleys. VSG-seq identified an average of 28 variants at each time point during the first 30 days of infection (Fig. 2C) . One mouse (mouse 3) survived much longer than did the other three (106 days, compared with 41 to 72 days). VSG identity has not been shown to affect growth rate or induction of the immune response (16, 17) , so the increased survival and lower diversity in this mouse are more likely due to the polyclonal germline B cell repertoire, which is unique to each mouse (18) , rather than the initiating VSG. Although in the later stages of this infection, VSG dynamics did appear qualitatively different-with variants persisting longer before clearance (Fig. 2B) , possibly owing to immune system exhaustionparasite populations remained diverse, with 30 to 66 variants detectable at each sampling (Fig. 2C) .
SCIENCE sciencemag.org 27 To see whether these infections showed any bias or hierarchy in VSG expression (6, 8, 19, 20) , we compared the VSG repertoires of all four mice. During the first 30 days of infection, 192 VSGs were expressed. Although each infection initiated with a different major VSG, the majority of variants (86%) appeared in more than one infection, and nearly half (46%) appeared in all four infections (Fig. 3C) . Ninety-seven VSGs were expressed in mouse 3 from days 96 to 105. We compared the later occurring VSGs with those expressed early in mice 1, 2, and 4 and found none in common, even though early variants from mouse 3 also appeared frequently in mice 1, 2, and 4 (Fig. 3D) .
Our experiments revealed striking diversity within each infection, but surprisingly frequent occurrence of the same VSGs in different infections.
Within these diverse populations, many variants appeared transiently. We have termed these "minor" variants. By examining the fate of every variant, we found that at any time during the first 30 days of infection, about half (53%) of the variants present will never reach 1% of the population (Fig. 3A) . Of the 48 VSGs that appeared in all four infections, few were consistently dominant, and few were only ever expressed as a minor variant (Fig. 3B) . This implies that variant success is not determined only by the expressed VSG. Instead, variant success is likely to be determined by interactions between the parasite and the humoral immune response in each animal. Because of antigenic similarity among some VSGs and their consequent elimination by crossreacting antibodies, the effective VSG repertoire will be smaller than the repertoire that the genome is capable of generating.
Besides losing variants to cross-reactivity, T. brucei's genomic VSG repertoire consists of a high proportion of incomplete VSG genes or pseudogenes (1, 21) . Indeed, the 289 VSGs observed in our infections may represent more than half of the complete VSG repertoire [~400 complete and predicted to be functional VSGs for the Lister427 strain (1), although the VSG repertoire for the EATRO1125 strain has not been fully elucidated]. The 65 to 135 VSGs observed before day 30 could represent up to 35% of the preexisting repertoire. Given the sampling frequency in our experiment, these values almost certainly underestimate the expressed VSG diversity in vivo. Therefore, much of the intact VSG repertoire is likely to have been expended early in an infection, as a result of expression and subsequent recognition by the immune system. As a result, the preexisting repertoire of complete VSGs would appear to be insufficient to support the sometimes years-long infections observed in the field. Although parasitemia is much lower in natural hosts, preexisting immunity is common in native mammals (22) , requiring constant VSG diversification to sustain infection.
Segmental gene conversion events have been demonstrated in both Trypanosoma equiperdum and T. brucei infections (7, 23, 24) generating "mosaic" VSGs that were not previously encoded in the genome. Previous studies had noted that mosaics tend to arise later in infection but have not determined when these variants are formed within the genome, or how. It is unknown whether mosaic VSGs form at the active expression site or within the silent repertoire before expression. To identify possible mosaics, we compared expressed VSG sequences to two independently assembled genomes for this parasite strain. Because of limitations in the amount of material available at each time point, we could choose only a few candidates for validation. To test that these were true mosaics and to determine when they formed within the genome, we used VSG-specific primers to confirm their absence from the genome of the parental strain and presence within genomic DNA (gDNA) collected during infection. We identified three mosaic VSGs using this approach. In each case, the mosaic VSG was only detectable by means of polymerase chain reaction (PCR) when it was also being expressed within the parasite population. This suggests that mosaic formation occurs, at least in these cases, shortly before expression, with subsequent transposition into the active expression site, or directly within the active expression site (Fig. 4 and  fig. S3 ). Mosaic formation may be a mechanism for increasing repertoire diversity as infection progresses.
Our results indicate that VSG switching does not occur at a rate that we would have expected to be just sufficient for immune evasion, with only a few variants present at any time. This suggests that recombinatorial mechanisms that expand the preexisting VSG repertoire may be critical for sustaining the long infections observed in natural hosts. Recent work on samples collected from sleeping sickness patients shows higherthan-expected VSG diversity (25) , indicating that complex VSG dynamics are likely to be clinically relevant. Our results provide a foundation for the study of VSG switching and diversification in vivo and demonstrate the potential of highthroughput approaches for studying antigenic variation, in trypanosomes and other parasitic diseases, in naturally infected humans and animals.
